<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Research - Ma Lab | UAB</title>
    <meta name="description" content="Cancer immunotherapy research focusing on DNA damage responses, POLE/POLD1 mutations, and checkpoint blockade mechanisms.">
    <link rel="stylesheet" href="styles.css">
</head>
<body>Pleas
    <nav class="navbar">
        <div class="nav-container">
            <div class="nav-logo">
                <h2><a href="index.html">Ma Lab</a></h2>
            </div>
            <ul class="nav-menu">
                <li><a href="index.html">Home</a></li>
                <li><a href="research.html" class="active">Research</a></li>
                <li><a href="people.html">People</a></li>
                <li><a href="publications.html">Publications</a></li>
                <li><a href="contact.html">Contact</a></li>
            </ul>
        </div>
    </nav>

    <main>
        <section class="section">
            <div class="container">
                <div class="research-overview">
                    <h2>Research Overview</h2>
                    <p>Ma Lab investigates the fundamental mechanisms of immune surveillance during cancer development and therapy. We focus on understanding how DNA damage responses, mutagenesis processes, and epigenetic disruptions shape tumor immunogenicity and influence treatment resistance, with the ultimate goal of developing novel cancer vaccines, TCR therapies, and combination treatments that maximize the potential of the immune system. </p>
                </div>

                <div class="research-directions">
                    <h2>Research Directions</h2>
                    <div class="research-grid">
                        <div class="research-card">
                            <div class="research-icon">ðŸ§¬</div>
                            <h3>DNA damage repair and tumor immunology</h3>
                            <p>Our previous research demonstrated that DNA damage repair deficiencies lead to accumulation of immunogenic mutations, fundamentally alter the tumor immune microenvironment, and enhance tumor sensitivity to immune checkpoint blockade therapy. However, the complex interplay between DNA damage response pathways and immune surveillance mechanisms in cancer requires deeper investigation to fully understand and therapeutically exploit. </p>
                            <div class="research-techniques">
                                <h4>Research Aims:</h4>
                                <ul>
                                    <li>Understanding how DNA damage repair deficient tumors developed primary and acquired resistance to immune checkpoint blockade therapies</li>
                                    <li>Characterizing DNA damage response in tumor-infiltrating immune cells and its impact on anti-tumor immunity.</li>
                                    <li>Exploring how biochemical features of neoantigen peptides determine the immunogenicity of the mutagenesis processes</li>
                                </ul>
                            </div>
                        </div>

                        <div class="research-card">
                            <div class="research-icon">ðŸŽ¯</div>
                            <h3>Immunological vulnerability of epigenetic dysregulated tumors</h3>
                            <p>Epigenetic dysregulation is a hallmark of cancer progression and drug resistance development. This dysregulation can also drive aberrant expression of non-canonical tumor antigens, potentially creating immunological vulnerabilities that may be targeted for therapeutic benefit.</p>
                            <div class="research-techniques">
                                <h4>Key Techniques:</h4>
                                <ul>
                                    <li>Elicidating the landscape of non-canonical tumor antigens associated with diverse epigenetic dysregulation in tumors</li>
                                    <li>Developing cancer vaccine and TCR therapies to target epigenetic dysregulation </li>
                                </ul>
                            </div>
                        </div>

                        <div class="research-directions">
                    <h2>Research Approaches</h2>
                    <div class="research-grid">
                        <div class="research-card">
                            <div class="research-icon">ðŸ§¬</div>
                            <p>Our research employs diverse experimental approaches including cellular and animal models, patient samples and clinical cohorts, synthetic biology tools, and computational immunogenomic analyses to investigate these fundamental questions.</p>
                        </div>


                <div class="funding-section">
                  
            </div>
        </section>
    </main>

    <footer>
        <div class="container">
            <div class="footer-content">
                <div class="footer-info">
                    <h3>Ma Lab</h3>
                    <p>Department of Genetics<br>
                    University of Alabama at Birmingham<br>
                    Birmingham, AL</p>
                </div>
                <div class="footer-contact">
                    <h3>Contact</h3>
                    <p>Email: <a href="mailto:xma2@uab.edu">xma2@uab.edu</a><br>
                    Phone: 205-934-5948</p>
                </div>
            </div>
            <div class="footer-bottom">
                <p>&copy; 2025 Ma Lab, University of Alabama at Birmingham. All rights reserved.</p>
            </div>
        </div>
    </footer>

    <script src="script.js"></script>
</body>
</html>
